CHISON MEDICAL(SH:688358) Sou Hu Cai Jing·2025-09-02 11:43Core Viewpoint - Xiangsheng Medical (688358) experienced a decline in stock price and significant net outflow of funds on September 2, 2025, indicating potential investor concerns about the company's performance and market sentiment [1][2]. Financial Performance - As of September 2, 2025, Xiangsheng Medical's stock closed at 29.94 yuan, down 4.35% with a trading volume of 26,200 hands and a transaction amount of 79.1551 million yuan [1]. - The company reported a main revenue of 236 million yuan for the first half of 2025, a year-on-year decrease of 4.61%, and a net profit attributable to shareholders of 69.6963 million yuan, down 14.32% year-on-year [3]. - In Q2 2025, the company achieved a single-quarter main revenue of 108 million yuan, up 1.37% year-on-year, but the net profit attributable to shareholders decreased by 21.57% to 28.0818 million yuan [3]. Market Position and Ratios - Xiangsheng Medical's total market value is 3.357 billion yuan, with a net asset of 1.378 billion yuan and a net profit of 69.6963 million yuan, ranking 98th, 90th, and 45th respectively in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 24.08, significantly lower than the industry average of 65.2, indicating a potentially undervalued stock [3]. - The gross margin stands at 60.65%, higher than the industry average of 51.85%, while the net margin is 29.51%, compared to the industry average of 10.39% [3]. Fund Flow Analysis - On September 2, 2025, the main funds saw a net outflow of 12.2648 million yuan, accounting for 15.49% of the total transaction amount, while retail investors had a net inflow of 14.9967 million yuan, representing 18.95% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating fund flows, with notable outflows from main funds on multiple days, indicating a trend of selling pressure [2]. Institutional Ratings - In the last 90 days, two institutions have given buy ratings for Xiangsheng Medical, suggesting some level of confidence in the company's future performance despite recent stock price declines [4].